Racial background is a determinant factor in the maintenance dosage of Warfarin
- 1 February 2003
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 78 (1) , 84-86
- https://doi.org/10.1007/bf02983247
Abstract
Warfarin is a drug commonly used in the prevention of thromboembolic events. There have been reports suggesting that racial background may influence warfarin dose requirements. Malaysia is a multiracial country in which there are 3 major races, Malay, Chinese, and Indian.We examined 100 patients from our hospital on stable maintenance doses of warfarin, with international normalized ratio (INR) of 2.0 to 3.5.We found that the mean warfarin dose for Indian patients (n = 19) was 6.9 mg, for Chinese patients (n = 55) was 3.6 mg, and for Malay patients (n = 26) was 3.2 mg.The results showed that the Indian patients required a statistically significantly higher warfarin dose than did patients of the other 2 races (P >.0005). Age was also found to affect the daily warfarin maintenance dose.Keywords
This publication has 8 references indexed in Scilit:
- Clinical relevance of genetic polymorphisms in the human CYP2C subfamilyBritish Journal of Clinical Pharmacology, 2001
- Pharmacogenetics of Warfarin Elimination and its Clinical ImplicationsClinical Pharmacokinetics, 2001
- Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0British Journal of Haematology, 1999
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Factors determining the maintenance dose of warfarin in Chinese patientsQJM: An International Journal of Medicine, 1996
- Effect of age upon the induction and maintenance of anticoagulation with warfarinPostgraduate Medical Journal, 1995
- Factors affecting the maintenance dose of warfarin.Journal of Clinical Pathology, 1992
- Differences in plasma binding of drugs between Caucasians and Chinese subjectsClinical Pharmacology & Therapeutics, 1990